Online inquiry

IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9271MR)

This product GTTS-WQ9271MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CEACAM5 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1048
UniProt ID P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9271MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2927MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ4986MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ15899MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ3552MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ9892MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ1159MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ4824MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ9721MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW